AffyImmune Therapeutics (@affyimmune) header
AffyImmune Therapeutics (@affyimmune) profile picture

Biotechnology startup developing Tune & Track platform to expand utility & improve safety of CAR T therapy for cancer.

Natick, MA
Joined August 2021
Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)Photo by AffyImmune Therapeutics (@affyimmune)
AffyImmune Appoints Drs. Rick Rutter and Jorge Nieva to Board of Directors The addition of these leaders in clinical development and manufacturing strengthens AffyImmune’s commitment to advancing its AIC100 program in #thyroidcancer and #NSCLC. businesswire.com/news/home/2…
1
1
158
Our CEO Daniel Janse is speaking on the Funding Biotech Innovation and Scaling up panel at @LSXLeaders #LSXWorldCongress
1
60
We’re excited to announce the appointment of Dr. Daniel Janse as President & CEO. Dr. Janse brings 20 years of expertise and an extensive background in #biopharma research and development, operations, and leadership. Read the release: businesswire.com/news/home/2…
46
AffyImmune Therapeutics retweeted
ASCO 2024: Anticipation mounts for the latest advancements in cancer treatment. Key companies, @AstraZeneca @DaiichiSankyoUS @Merck @affyimmune @Genmab, and others are prepared to unveil highlights in Head and Neck Cancer. For More: tinyurl.com/y42rabta #ASCO2024
1
4
294
AffyImmune Therapeutics retweeted
AffyImmune’s CAR-T sees first-ever complete response in solid tumour $AFFY #ASCO24 firstwordpharma.com/story/58…
2
4
1,011
AffyImmune Therapeutics retweeted
. @AffyImmune has recorded what it says is the first complete response in a patient with a solid tumour treated with CAR-T therapy at #ASCO24. #thyroidcancer pharmaphorum.com/news/asco-a…
3
3
341
For evaluable patients in DL2 (100 million CAR T cells) and DL3 (500m CAR T cells) (n=6), the ORR was 33%, with one pt at DL2 achieving a durable partial response (PR) and another patient at DL3 achieving an ongoing durable mCR allowing the pt to be off all chemo. DCR was 67%.
49
As of the data cutoff date, 10 patients (6 ATC; 4 PDTC) were infused with AIC100 at 3 dose levels (DLs). No dose-limiting toxicities were observed across all dose levels, and the maximum tolerated dose was not reached.
41
AffyImmune Therapeutics retweeted
I'm very pleased to serve on the Clinical and Regulatory Advisory Board of @affyimmune - Hagop Youssoufian #Cancer #Career #CARTTherapies #LungCancer #OncoDaily #Oncology #ThyroidCancer #Biotechnology oncodaily.com/47136.html
3
17
356